How the newest antibiotics attack bacteria that resist the old ones

The newest antibiotics attack resistance by changing the target. Most resistance is specific: bacteria acquire enzymes that destroy penicillin-like drugs or pumps that eject familiar molecules. Newer agents bind structures the old families never attacked — a 2025 U.S. approval for gepotidacin, the first new antibiotic class cleared for urinary tract infections in decades, exploits an enzyme-DNA complex that earlier drugs left alone. The pipeline is thin, but for the first time in a generation it is not empty.

Engevity News publishes information about research, not medical advice. Antibiotic choice is a clinical decision; misuse fuels resistance.

How does resistance actually work?

Bacteria evolve under antibiotic pressure, and they use a short list of strategies. Some build enzymes that chemically dismantle the drug — the classic example is beta-lactamase, which cleaves penicillins. Some mutate the molecular target the drug binds, so the drug no longer fits. Some install pumps that eject the drug faster than it accumulates, or thicken their outer wall to bar entry. Resistance genes travel between bacteria on mobile DNA fragments, which is why a resistance trait that arose in a harmless soil organism can end up in a hospital pathogen. The World Health Organization, which updated its list of priority resistant pathogens in May 2024, ranks carbapenem-resistant strains among the highest threats.

Why did the antibiotic pipeline run dry?

Economics, mostly. A successful antibiotic is used briefly, priced low, and shelved to preserve its usefulness — the opposite of a profitable drug. Large pharmaceutical companies largely withdrew from the field through the 2000s and 2010s, and approvals hit lows in the late 2010s. Academic laboratories and small biotechnology firms carried the science: publicly funded work at universities, often with backing from public-private partnerships such as CARB-X, founded in 2016, produced many of the candidates now reaching trials.

What makes an antibiotic genuinely new?

Novelty means a new chemical class attacking a new target, not a tweaked version of an old molecule. Three examples define the current wave. Gepotidacin, developed by GlaxoSmithKline, inhibits bacterial topoisomerases — enzymes that untangle DNA during replication — by binding a site different from older fluoroquinolones, which lets it evade common resistance. The U.S. Food and Drug Administration approved it in March 2025 for urinary tract infections, making it the first new antibiotic class for that indication in more than twenty years. Zosurabalpi, identified by Roche researchers with partners and described in Nature in 2023, targets a molecule that carries the outer membrane of Acinetobacter — a bacterium resistant to nearly everything — and remains in clinical trials. Fosfomycin-based and siderophore-equipped candidates, which smuggle themselves into bacteria by mimicking the nutrients they scavenge, represent the same philosophy: enter differently, bind differently.

How do we know the new drugs work and are safe?

Through the standard machinery of trials. Gepotidacin's approval rested on two phase 3 trials in which it outperformed an established drug for uncomplicated urinary infections — results GSK announced in 2024 and regulators reviewed before the 2025 approval. Zosurabalpi has reported early-phase safety data and is being tested against carbapenem-resistant Acinetobacter infections in hospitalized patients; its published laboratory results, including infection models in animals, established the mechanism, but clinical outcomes are still being collected. The honest caveats: approvals for resistant infections are often based on smaller trials than other drugs receive, because eligible patients are few; and any antibiotic's usefulness can erode as resistance evolves. A drug that evades today's enzymes is not immune to tomorrow's.

Can resistance be delayed rather than just outrun?

Partially. Combination therapy — attacking two targets at once — makes it statistically harder for bacteria to evolve escape, a lesson from tuberculosis and HIV treatment. Diagnostic tests that identify the responsible bacterium and its weaknesses within hours, rather than days, let doctors prescribe narrowly; rapid molecular assays for resistance genes have been entering clinical use since the 2010s. And stewardship programs, which the U.S. Centers for Disease Control and Prevention has promoted for years, slow the selective pressure that breeds resistance in the first place. None of these is a triumph; each is friction against a fast-evolving opponent.

Do phages and other alternatives compete with new antibiotics?

Bacteriophages — viruses that infect bacteria — predate antibiotics as a treatment idea and have returned to clinical use in a narrow way: under compassionate-use programs, customized phage cocktails have treated individual patients with pan-resistant infections since high-profile cases in 2018 onward, and randomized trials began reporting results in the 2020s. The approach faces obstacles antibiotics do not: phages are specific to particular strains, often require custom preparation, and bacteria evolve resistance to them too. Most specialists view phages as a complement for desperate cases rather than a replacement pipeline, and the same holds for antimicrobial peptides and antibodies in trials.

Is the pipeline enough?

Not yet, by the World Health Organization's own assessments. The 2024 priority-pathogen list and the agency's pipeline reviews note that most candidates are derivatives of existing classes, active against the easier gram-positive threats, while the deadliest gram-negative bacteria attract the fewest novel candidates. Incentive experiments — subscription payment models piloted in the United Kingdom from 2019, and milestone prizes proposed in the United States — attempt to repair the economics. The science, after a long drought, is again producing ideas. Whether the market lets them survive is a separate, unresolved question.